Trifluoperazine: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +)
Vignesh Ponnusamy (talk | contribs)
nocaptcha
7,606 edits
No edit summary
Line 1: Line 1:
{{drugbox |
{{DrugProjectFormSinglePage
| IUPAC_name = ''10-[3-(4-methylpiperazin-1-yl)propyl]-<br/>2-(trifluoromethyl)-10''H''-phenothiazine''
|authorTag=
| image = Trifluoperazine.png
 
| width = 185
{{VP}}
| CAS_number = 117-89-5
 
| ATC_prefix = N05
<!--Overview-->
| ATC_suffix = AB06
 
| PubChem = 5566
|genericName=
| DrugBank = APRD00173
 
| C=21 | H=24 | F=3 | N=3 | S=1
 
| molecular_weight = 407.497
 
| bioavailability =  
|aOrAn=
| metabolism = [[Hepatic]]
 
| elimination_half-life = 10-20 hours
a
| excretion =  
 
| pregnancy_category =  
|drugClass=
| legal_status =  
 
| routes_of_administration = oral, [[IM]]
 
}}
 
|indication=
 
 
 
|hasBlackBoxWarning=
 
Yes
 
|adverseReactions=
 
 
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* Condition1
 
<!--Warnings-->
 
|warnings=
 
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
* Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
 
 
<!--Mechanism of Action-->
 
|mechAction=
 
*
 
<!--Structure-->
 
|structure=
 
*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
 
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
 
|clinicalStudies=


'''Trifluoperazine''' (sold as '''Eskazinyl''', '''Eskazine''', '''Jatroneural''', '''Modalina''', '''Stelazine''', '''Terfluzine''', '''Trifluoperaz''') is a [[typical antipsychotic]] [[medication|drug]] of the [[phenothiazine]] group. It exerts its actions through a central adrenergic-blocking, a [[dopamine]]-blocking, and minimal [[anticholinergic]] blocking. <ref>"Facts and Comparisons" III W. Port Plaza, Suite 300 St. Louis MO. USA 63146-3098 (telephone 314-216-2100 or 1-800-223-0554). (Note this book is currently used by Rite Aid Pharmacies in the USA as a reference aid and it is a loose bound updatable book. The updatable section called "Antipsychotic Agents" is (c)1990</ref>
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.


== Pharmacokinetics ==
<!--How Supplied-->
Little is known about human pharmacokinetics. One study has the following results:
A study of the pharmacokinetics of trifluoperazine as a single 5-mg dose by mouth in 5 healthy subjects. Peak plasma concentrations of trifluoperazine were reached from 1.5 to 4.5 hours after ingestion and varied widely between subjects, ranging from 0.53 to 3.09 ng per mL. Elimination of trifluoperazine was multiphasic; the mean elimination half-life was estimated to be 5.1 hours over the period from 4.5 to 12 hours after ingestion, while the mean apparent terminal elimination half-life was estimated to be 12.5 hours to 13.6 hours.


== Uses ==
|howSupplied=
<!--  Commented out because image was deleted: [[Image:StelazineAd.png|thumb|250px|left|Historical advertisement for Stelazine from 1989]] -->
The primarary indication of trifluoperazine is [[schizophrenia]]. Its use in  many parts of the world has declined because of highly frequent and severe early and late [[tardive dyskinesia]], a type of  [[extrapyramidal symptom]].  The annual development rate of tardive dyskinesia may be as high as 4%.


Studies suggest that trifluoperazine may be able to reverse addiction to opioids. [http://www.sciencedaily.com/releases/2006/02/060213092323.htm]
*


== Indications in Canada ==
<!--Patient Counseling Information-->


Indications in Canada for trifluoperazine include:
|fdaPatientInfo=


1. Anxiety states: it controls excessive anxiety, tension and agitation seen in neuroses or associated with somatic conditions.
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


2. The treatment or prevention of nausea and vomiting of various causes.
<!--Precautions with Alcohol-->


3. The management of psychotic disorders, such as acute or chronic catatonic, hebephrenic and paranoid schizophrenia; psychosis due to organic brain damage, toxic psychosis, and the manic phase of manic-depressive illness.
|alcohol=


Phillip W. Long, M.D. [http://www.mentalhealth.com/drug/p30-s04.html Trifluoperazine].
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


Indications may vary in different countries.
<!--Brand Names-->


== Side effects ==
|brandNames=
For further information see: [[phenothiazine]]


Serious side effects include [[akathisia]], [[tardive dyskinesia]] and the potentially fatal [[neuroleptic malignant syndrome]].
* ®<ref>{{Cite web | title =  | url =  }}</ref>


A particular severe form of liver damage has been reported, making preexisting liver damage a contraindication.
<!--Look-Alike Drug Names-->


== Formulations ==
|lookAlike=
In the past, trifluoperazine was used in fixed combinations with the [[MAO inhibitor]] (antidepressant) [[tranylcypromine]] to attenuate the strong stimulating effects of this antidepressant. This combination was sold under the brand name Jatrosom. Likeweise a combination with [[amobarbital]] (strong sedative/hypnotic agent) for the amelioration of [[psychoneurosis]] and [[insomnia]] existed under the brand name Jalonac. Both combinations are not available any longer.


The drug is sold as tablet, liquid and 'Trifluperazine-injectable USP' for deep [[intramuscular|IM]] short-term use.
* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>


== Trivia ==
<!--Drug Shortage Status-->


In [[Philip K. Dick]]'s novel [[A Maze of Death]], the character Betty Jo Berm mentions, while describing an assortment of pills that she takes, "... "The blue ones are stelazine, which I use as an [[anti-emetic]]. You understand: I use it for that, but that isn't it's basic purpose. Basically Stelazine is a [[tranquilizer]], in doses of less that twenty milligrams a day. In greater doses it's an anti-[[hallucinogenic]] agent. But I don't take it for that either. Now, the problem with stelazine is that it's a [[vasodilator]]."..."
|drugShortage=
}}


==References==
<!--Pill Image-->
{{reflist|2}}
{{refimprove|date=November 2006}}


{{Antipsychotics}}
{{PillImage
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}


<!--Label Display Image-->


==References==
{{LabelImage
{{reflist|2}}
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}
 
{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


<!-- Categories -->
<!--Category-->
[[Category:Typical antipsychotics]]


<!--Other languages-->
[[Category:Drug]]
[[ru:Трифлуоперазин]]

Revision as of 16:41, 22 January 2015

Trifluoperazine
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vignesh Ponnusamy, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content

Overview

Trifluoperazine is a that is FDA approved for the {{{indicationType}}} of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Trifluoperazine in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Trifluoperazine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Trifluoperazine in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Trifluoperazine in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Trifluoperazine in pediatric patients.

Contraindications

  • Condition1

Warnings

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Trifluoperazine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Trifluoperazine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Trifluoperazine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Trifluoperazine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Trifluoperazine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Trifluoperazine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Trifluoperazine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Trifluoperazine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Trifluoperazine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Trifluoperazine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Trifluoperazine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Trifluoperazine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Trifluoperazine in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Trifluoperazine in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Trifluoperazine in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Trifluoperazine in the drug label.

Pharmacology

There is limited information regarding Trifluoperazine Pharmacology in the drug label.

Mechanism of Action

Structure

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Trifluoperazine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Trifluoperazine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Trifluoperazine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Trifluoperazine in the drug label.

How Supplied

Storage

There is limited information regarding Trifluoperazine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Trifluoperazine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Trifluoperazine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Trifluoperazine in the drug label.

Precautions with Alcohol

  • Alcohol-Trifluoperazine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Trifluoperazine
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Trifluoperazine
 |Label Name=Trifluoperazine11.png

}}


{{#subobject: 

 |Label Page=Trifluoperazine
 |Label Name=Trifluoperazine11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Trifluoperazine&oldid=1058267"